Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
0.930
-0.130 (-12.25%)
At close: Apr 28, 2026, 4:00 PM EDT
0.929
-0.001 (-0.15%)
After-hours: Apr 28, 2026, 4:50 PM EDT
Skye Bioscience Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Skye Bioscience stock have an average target of 15, with a low estimate of 10 and a high estimate of 20. The average target predicts an increase of 1,512.73% from the current stock price of 0.93.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 30, 2025.
Analyst Ratings
The average analyst rating for Skye Bioscience stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +2,050.31% | Sep 30, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $10 | Buy | Initiates | $10 | +975.15% | Aug 15, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $15 | Buy | Reiterates | $15 | +1,512.73% | Jun 24, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +1,405.21% | Mar 21, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $15 | Buy | Reiterates | $15 | +1,512.73% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.03
from -1.41
EPS Next Year
-1.21
from -1.03
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.67 | -0.66 | ||||||
| Avg | -1.03 | -1.21 | ||||||
| Low | -1.41 | -1.68 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.